Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

1. Age ≥ 50 years and ≤ 89 years

2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye

3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the study eye previously treated with anti-VEGF

4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye

5. Willing and able to provide written, signed informed consent for this study

6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry

1. CNV or macular edema in the study eye secondary to any causes other than AMD

2. Subfoveal fibrosis or atrophy in the study eye

3. Any condition in the investigator's opinion that could limit VA improvement in the study eye

4. Active or history of retinal detachment, or current retinal tear that cannot be treated, in the study eye

5. Advanced glaucoma or history of secondary glaucoma in the study eye

6. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months.

7. History of intraocular surgery in the study eye within 12 weeks prior to randomization

8. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product, other than anti-VEGF therapy, in the 6 months prior to Screening Visit 1.

9. Prior treatment with gene therapy.